Activation of neurotensin receptors and purinoceptors in human colonic adenocarcinoma cells detected with the microphysiometer

Biochemical Pharmacology

Volumn 54, Issue 7, 1997, Pages 825-832

  Richards, Mary ^a   Van Giersbergen, Paul ^a,b   Zimmermann, André ^a   Lesur, Brigitte ^a,c   Hoflack, Jan ^a,d  

^a SANOFI   (France)

^b Clin Pharma Research Ltd   (Switzerland)

^c Laboratoire L Lafon   (France)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

HT 29; Microphysiometer; NT receptor; P2 purinoceptor

Indexed keywords

NEUROTENSIN; NEUROTENSIN DERIVATIVE; NEUROTENSIN RECEPTOR; PURINE P2 RECEPTOR;

ARTICLE; BIOSENSOR; CELL CULTURE; CELL LINE; CELL METABOLISM; COLON ADENOCARCINOMA; CONTROLLED STUDY; DESENSITIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; TECHNIQUE;

ADENOSINE TRIPHOSPHATE; DOSE-RESPONSE RELATIONSHIP, DRUG; HT29 CELLS; HUMANS; NEUROTENSIN; RECEPTORS, NEUROTENSIN; RECEPTORS, PURINERGIC P2; TACHYPHYLAXIS;

EID: 0030776411     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00258-X     Document Type: Article

References (28)

1. 2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy. Proc Natl Acad Sci USA 91: 3275-3279, 1994.
2. Amar S, Kitabgi P and Vincent J-P, Activation of phosphatidylinositol turnover by neurotensin receptors in the human colonic adenocarcinoma cell line HT29. FEBS Lett 201: 31-36, 1986.
3. Turner JT, James-Kracke MR and Camden JM, Regulation of the neurotensin receptor and intracellular calcium mobilization in HT29 cells. J Pharmacol Exp Ther 253: 1049-1056, 1990.
4. Vita N, Laurent P, Lefort S, Chalon P, Dumont X, Kaghad M, Gully D, Le Fur G, Ferrara P and Caput D, Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett 317: 139-142, 1993.
5. Maoret J-J, Pospai D, Rouyer-Ferrard C, Couvineau A, Laboisse C, Voisin T and Laburthe M, Neurotensin receptor and its mRNA are expressed in many human colonic cell lines but not in normal colonic epithelium: binding studies and RT-PCR experiments. Biochem Biophys Res Commun 203: 465-471, 1994.
6. αMeArg-Lys-Pro-Trp-tLeu-Leu (NT1). Biochem Pharmacol 49: 1147-1154, 1995.
7. Fredholm BB, Purinoceptors in the nervous system. Pharmacol Toxicol 76: 228-279, 1995.
8. Amar S, Mazella J, Checler K, Kitabgi P and Vincent JP, Regulation of cyclic GMP levels by neurotensin in neuroblastoma clone N1E-115. Biochem Biophys Res Commun 129: 117-125, 1985.
9. Gilbert JA, Moses CJ, Pfenning MA and Richelson E, Neurotensin and its analogs: correlation of specific binding with stimulation of cyclic GMP formation in neuroblastoma clone N1E-115. Biochem Pharmacol 35: 391-397, 1986.
10. Tanaka K, Masu M and Nakanishi S, Structure and functional expression of the cloned rat neurotensin receptor. Neuron 4: 847-854, 1990.
11. Owicki JC and Parce JW, Biosensors based on the energy metabolism of living cells: the physical chemistry and cell biology of extracellular acidification. Biosens Bioelectron 7: 255-272, 1992.
12. McConnell HM, Owicki JC, Parce JW, Miller DL, Baxter GT, Wada HG and Pitchford S, The cytosensor microphysiometer: biological applications of silicon technology. Science 257: 1906-1912, 1992.
13. McConnell HM, Rice P, Wada GH, Owicki JC and Parce JW, The microphysiometer biosensor. Curr Opin Struct Biol 1: 647-652, 1992.
14. Baxter GT, Young ML, Miller DL and Ozicki JC, Using microphysiometer to study the pharmacology of exogenously expressed m1 and m3 muscarinic receptors. Life Sci 55: 573-583, 1994.
15. Parce JW, Owicki JC, Kercso KM, Sigal GB, Wada HG, Muir VC, Bousse LJ, Ross KL, Sikic BI and McConnell HM, Detection of cell-affecting agents with a silicon biosensor. Science 246: 243-247, 1989.
16. Bradford MM, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Chem 72: 248-254, 1976.
17. Richards MH and van Giersbergen PLM, Human muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonists. Br J Pharmocol 114: 1241-1249, 1995.
18. Pugsley TA, Akunne HC, Whetzel SZ, Demattos S, Corbin AE, Wiley JN, Wustrow DJ, Wise LD and Heffner TG, Differential effects of the nonpeptide neurotensin antagonist, SR 48692, on pharmacological effects of neurotensin agonists. Peptides 16: 37-44, 1995.
19. Mazella J, Leonard K, Chabry J, Kitabgi P, Vincent J-P and Beaudet A, Binding and internalization of iodinated neurotensin in the neuronal cultures from embryonic mouse brain. Brain Res 564: 249-255, 1991.
20. Chabry J, Gaudriault G, Vincent J-P and Mazella J, Implication of various forms of neurotensin receptors in the mechanism of internalization of neurotensin in cerebral neurons. J Biol Chem 268: 17138-17144, 1993.
21. S interfere with receptor down-regulation but not sequestration. Mol Pharmacol 39: 192-198, 1991.
22. P in receptor compartmentation. J Biol Chem 266: 23856-23862, 1991.
23. Yamada M, Yamada M and Richelson E, Role of signal transduction systems in neurotensin receptor down-regulation induced by agonist in murine neuroblastoma clone N1E-115 cells. J Pharmacol Exp Ther 267: 128-133, 1993.
24. Pals-Rylaarsdam R, Xu Y, Witt-Enderby P, Benovic JL and Hosey MM, Desensitization and internalization of the m2 muscarinic acetylcholine receptor are directed by independent mechanisms. J Biol Chem 270: 29004-29011, 1995.
25. 2A-adrenergic receptor. J Biol Chem 270: 4681-4688, 1995.
26. 3H]SR48692, in guinea pig brain. J Pharmacol Exp Ther 273: 1450-1458, 1995.
27. 3H]SR48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor. Mol Pharmacol 47: 1050-1056, 1995.
28. Richards MH, Pharmacology and second messenger interactions of cloned muscarinic receptors. Biochem Pharmacol 42: 1645-1653, 1991.